Dr Koen Deloose (AZ Sint-Blasius, Dendermonde, BE) discusses the 24-month outcomes of the TINTIN trial.
The trial investigates the safety and efficacy of the combination therapy with the Luminor drug-coated balloon (DCB) and the iVolution stent in the treatment of TASC C and D femoropopliteal lesions.
1. What was the rationale for this trial and what guided the selection of these two products?
3. What were the key results?
4. What are the 'take-home' messages for clinicians?
5. What further research is required?
Recorded remotely from Dendermonde, 2021.
Editor: Mirjam Boros
Recording Editor: Natascha Wienand